FMP

FMP

Enter

REPL - Replimune Group...

photo-url-https://images.financialmodelingprep.com/symbol/REPL.png

Replimune Group, Inc.

REPL

NASDAQ

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

10.14 USD

-0.22 (-2.17%)

Historical Prices

From:

To:

10.0510.110.1510.210.2510.310.3510.3909:30 AM09:47 AM10:05 AM10:29 AM10:50 AM11:05 AM11:22 AM11:37 AM11:58 AM12:13 PM12:39 PM01:04 PM01:28 PM01:47 PM02:09 PM02:40 PM03:02 PM03:20 PM03:34 PM03:48 PM

About

ceo

Dr. Sushil Patel Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise cause...

CIK

0001737953

ISIN

US76029N1063

CUSIP

76029N106

Address

500 Unicorn Park Drive

Phone

781 222 9600

Country

US

Employee

331

IPO Date

Jul 20, 2018

Financial Statement

-70M-60M-50M-40M-30M-20M-10M010M2024 Q22024 Q32024 Q42025 Q12025 Q2RevenueNet Income

Earnings

-1-0.8-0.6-0.4-0.202023 Q12023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q4EPS Consensus

REPL Financial Summary

CIK

0001737953

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

76029N106

ISIN

US76029N1063

Country

US

Price

10.14

Beta

1.19

Volume Avg.

803.93k

Market Cap

763.95M

Shares

-

52-Week

4.92-17.0

DCF

-0.02

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-3.34

P/B

-

Website

https://www.replimune.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest REPL News

GlobeNewsWire

Jul 30, 2024

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will host investor meetings at the following two conferences:

Zacks Investment Research

Jun 7, 2024

Replimune (REPL) Gains on Positive Data From Melanoma Study

Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.

GlobeNewsWire

Jun 7, 2024

Replimune to Present at the Goldman Sachs 45th Annual Global...

WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:00 PM ET.

GlobeNewsWire

May 23, 2024

Replimune to Present at the 2024 American Society of Clinica...

WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4, 2024.

Zacks Investment Research

Mar 11, 2024

How Much Upside is Left in Replimune Group, Inc. (REPL)? Wal...

The average of price targets set by Wall Street analysts indicates a potential upside of 50.2% in Replimune Group, Inc. (REPL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research

Mar 8, 2024

What Makes Replimune Group, Inc. (REPL) a New Buy Stock

Replimune Group, Inc. (REPL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research

Feb 23, 2024

Wall Street Analysts See a 70.57% Upside in Replimune Group,...

The consensus price target hints at a 70.6% upside potential for Replimune Group, Inc. (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

GlobeNewsWire

Dec 28, 2023

Replimune to Present at the 42nd Annual J.P. Morgan Healthca...

WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 AM PT at the Westin St. Francis Hotel in San Francisco, CA.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep